Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Edoxaban for the Treatment of Coagulopathy in Patients With Active Cancer and Acute Ischemic Stroke: a Pilot Study. (ENCHASE Study)

NCT03570281 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT03570281
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03570281 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Edoxaban for the Treatment of Coagulopathy in Patients With Active Cancer and Acute Ischemic Stroke: a Pilot Study. (ENCHASE Study)
Lead sponsor
Samsung Medical Center
Phase
Phase 2/3
Overall status
Unknown status
Start date
June 15, 2018
Completion date
November 30, 2020
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

correction of cancer-related coagulopathy with novel oral anticoagulant (edoxaban)